Name: | Methyldopa | Synonyms: | ;L-A-METHYL DOPA MK-351, METHYLDOPA;MethyldopaUsp28/Bp2003/Ep5;3-Hydroxy-α-methyl-L-tyrosine;L-Tyrosine, 3-hydroxy-.alpha.-methyl-;2-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE |
---|---|---|---|
Cas No: | 555-30-6 | Ec No: | 209-089-2 |
Molecular Formula: | C10H13NO4 | Molecular Weight: | 211.22 |
Melting Point: | ≥300 °C | Boiling Point: | 350.89°C |
Density: | 1.2545 | ||
High Light: | 555-30-6 Alpha Methyldopa Api Receptor Dopamine,Cas 555 30-6 Alpha Methyldopa Api Dopamine,alpha methyldopa api dopamine receptors 555-30-6 |
Methyldopa;CAS 555-30-6;API;
Name | Methyldopa |
Synonyms | ;L-A-METHYL DOPA MK-351, METHYLDOPA;MethyldopaUsp28/Bp2003/Ep5;3-Hydroxy-α-methyl-L-tyrosine;L-Tyrosine, 3-hydroxy-.alpha.-methyl-;2-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE |
Molecular Formula | C10H13NO4 |
Molecular Weight | 211.22 |
CAS Registry Number | 555-30-6 |
EINECS Number | 209-089-2 |
Melting point | ≥300 °C |
density | 1.2545 |
Boiling point | 350.89°C |
Product Description:
Methyldopa is an α-methoxylated derivative of levodopa that exhibits hypotensive action by reducing overall peripheral vascular resistance and reducing heart work. Antihypertensive action of methyldopa consists of the biotransformation of methyldopa into methylnoradrenaline (methylnorepinephrine), which acts as a “pseudo neurotransmitter.” The current, universally accepted point of view is that the action of methyldopa is carried out through the CNS, where methylnorepinephrine, a powerful stimulant of α-adrenergic receptors of the medulla, inhibits the vasomotor center.
Product Use:
α-Methyldopa is not generally believed to be suitable for monotherapy of primary hypertension. Because plasma volume increases as the duration of α-methyldopa therapy is extended, the drug should be used in conjunction with a diuretic; this will produce a significantly greater fall in blood pressure than would occur with either drug used alone. Because α-methyldopa lowers blood pressure without compromising either renal blood flow or the glomerular filtration rate, it is particularly valuable in hypertension complicated by renal disease. However, if end-stage renal failure accompanies severe hypertension,α-methyldopa may not be effective.
The presence of α-methyldopa and its metabolites in the urine reduces the diagnostic value of urinary catecholamine measurements as an indicator of pheochromocytoma, since these substances interfere with the fluorescence assay for catecholamines.
Number | Cas | Name |
1 | 62-46-4 | Alpha Lipoic Acid |
2 | 303-98-0 | Coenzyme Q10 |
3 | 6020-87-7 | Creatine Monohydrate |
4 | 110-17-8 | Fumaric Acid |
5 | 3416-24-8 | Glucosamine |
6 | 87-89-8 | Inositol |
7 | 73-22-3 | L-Tryptophan |
8 | 56-87-1 | L-Lysine |
9 | 24634-61-5 | Potassium Sorbate |
10 | 56038-13-2 | Sucralose |
11 | 107-35-7 | Taurine |
12 | 128-13-2 | Ursodeoxycholic Acid/ UDCA |
13 | 59-43-8 | Vitamin B1 |
14 | 83-88-5 | Vitamin B2 |
15 | 8059-24-310 | Vitamin B6 |
16 | 68-19-9 | Vitamin B12 |
17 | 50-81-7 | Vitamin C |
18 | 1406-18-4 | Vitamin E |
19 | 11138-66-2 | Xanthan Gum |
About us
Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.
In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.
In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.